| Not Yet Recruiting | Study of QLS5308 in Patients With Advanced Solid Tumors NCT07462442 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers NCT07238075 | Adcytherix SAS | Phase 1 |
| Recruiting | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic Lesio NCT07333664 | Li Min | Phase 2 |
| Not Yet Recruiting | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) NCT07307053 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Met NCT07272590 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. NCT07224464 | New Phase Ltd. | N/A |
| Not Yet Recruiting | A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases NCT07249892 | Chengdu Syncor Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastat NCT07215637 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Recruiting | A Study of DS3610a in Participants With Advanced Solid Tumor NCT07159126 | Daiichi Sankyo | Phase 1 |
| Recruiting | BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or NCT07193511 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | SLV-324 Treatment of Metastatic Solid Tumors NCT07108114 | Solve Therapeutics | Phase 1 |
| Recruiting | A Study of SKB107 in Advanced Solid Tumors With Bone Metastases NCT07087197 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. NCT07021898 | Erasca, Inc. | Phase 1 |
| Not Yet Recruiting | A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1 NCT07046780 | PENG YUAN | — |
| Active Not Recruiting | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors NCT06873789 | Incyte Corporation | Phase 1 / Phase 2 |
| Recruiting | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors NCT06983743 | Erasca, Inc. | Phase 1 |
| Recruiting | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced NCT07038343 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) NCT06660654 | Daiichi Sankyo | Phase 2 |
| Recruiting | Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tum NCT06770764 | Trutino Biosciences Inc. | Phase 1 |
| Recruiting | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advan NCT06585488 | BeiGene | Phase 1 |
| Not Yet Recruiting | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss NCT06614751 | Danatlas Pharmaceuticals Co., Ltd | Phase 1 |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combinati NCT06031441 | Genentech, Inc. | Phase 1 |
| Recruiting | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors NCT05836324 | Incyte Corporation | Phase 1 |
| Recruiting | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) NCT05853367 | Merck Sharp & Dohme LLC | Phase 1 |
| Active Not Recruiting | NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated NCT05605496 | Centre Leon Berard | Phase 2 |
| Completed | 90-Day Mortality After Emergency Department Discharge in Advanced Cancer NCT07167095 | Ankara Etlik City Hospital | — |
| Completed | First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors NCT05494918 | Alphamab (Australia) Co Pty Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in NCT05487235 | Genentech, Inc. | Phase 1 |
| Completed | M1231 in Participants With Solid Tumors NCT04695847 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Completed | Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan NCT04319198 | Gilead Sciences | Phase 4 |
| Completed | First in Human Study of M6223 NCT04457778 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Recruiting | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations NCT04094610 | Turning Point Therapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alteration NCT03993873 | Turning Point Therapeutics, Inc. | Phase 1 |
| Completed | A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors NCT03910530 | Incyte Biosciences Japan GK | Phase 1 |
| Active Not Recruiting | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABB NCT03893955 | AbbVie | Phase 1 |
| Completed | Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 NCT03697304 | Boehringer Ingelheim | Phase 2 |
| Terminated | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors NCT03854227 | Pfizer | Phase 1 |
| Terminated | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Canc NCT03809624 | Inhibrx Biosciences, Inc | Phase 1 |
| Completed | ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors NCT03802123 | ImaginAb, Inc. | Phase 2 |
| Withdrawn | Imaging of Advanced Tumours Using [131]I-IAZA NCT03427320 | University of Alberta | Phase 1 / Phase 2 |
| Unknown | A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors NCT03646071 | NeuPharma, Inc. | Phase 1 |
| Terminated | This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Me NCT03573544 | OBI Pharma, Inc | Phase 1 / Phase 2 |
| Completed | Phase I/Ib Multiple Ascending Dose Study in China NCT03523390 | Merck KGaA, Darmstadt, Germany | Phase 1 |
| Completed | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With R NCT03388632 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I S NCT03403725 | Menarini Group | Phase 1 |
| Recruiting | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rea NCT03093116 | Turning Point Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors NCT03059823 | Incyte Corporation | Phase 1 |
| Completed | A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study NCT04010240 | Institut Bergonié | — |
| Completed | Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/o NCT02281409 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Sol NCT02235688 | ImmunityBio, Inc. | Phase 1 |
| Completed | Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NT NCT02097810 | Hoffmann-La Roche | Phase 1 |
| Terminated | A Study of DCC-2701 in Participants With Advanced Solid Tumors NCT02228811 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Completed | A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc NCT01976143 | Nektar Therapeutics | Phase 1 |
| Completed | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With NCT02045602 | Theriva Biologics SL | Phase 1 |
| Completed | Phase 1b Trial of BGJ398/BYL719 in Solid Tumors NCT01928459 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patien NCT01847118 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors NCT01543763 | Pamela Munster | Phase 1 |
| Completed | Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer NCT01449370 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel a NCT00793897 | Bristol-Myers Squibb | Phase 1 |
| Suspended | A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors NCT00827203 | Synta Pharmaceuticals Corp. | Phase 1 |
| Completed | Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors NCT00878423 | Astex Pharmaceuticals, Inc. | Phase 1 |
| Completed | Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) NCT00670488 | Merck Sharp & Dohme LLC | Phase 1 |
| Withdrawn | Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study. NCT00159016 | Hadassah Medical Organization | Phase 2 |
| Withdrawn | Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies. NCT00149019 | Hadassah Medical Organization | Phase 2 |
| Withdrawn | Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors NCT00148993 | Hadassah Medical Organization | Phase 1 / Phase 2 |